194 related articles for article (PubMed ID: 25892936)
1. Presentation of acute central retinal vein occlusion in scleroderma.
Malik F; Al Habash A
Saudi J Ophthalmol; 2015; 29(2):156-9. PubMed ID: 25892936
[TBL] [Abstract][Full Text] [Related]
2. Central retinal vein occlusion: A patient with systemic sclerosis.
Karadžić J; Radosavljević A; Kovačević I
Vojnosanit Pregl; 2016 Sep; 73(9):868-72. PubMed ID: 29320621
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.
Januschowski K; Feltgen N; Pielen A; Spitzer B; Rehak M; Spital G; Dimopoulos S; ; Meyer CH; Szurman GB
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):457-462. PubMed ID: 27632214
[TBL] [Abstract][Full Text] [Related]
5. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.
Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C
Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
7. Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial.
Motarjemizadeh G; Rajabzadeh M; Aidenloo NS; Valizadeh R
Electron Physician; 2017 Aug; 9(8):5068-5074. PubMed ID: 28979743
[TBL] [Abstract][Full Text] [Related]
8. The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions.
Ivanovska Adjievska B; Boskurt S; Orovcanec N; Dimovska-Jordanova V
Clin Ophthalmol; 2017; 11():1183-1190. PubMed ID: 28790803
[TBL] [Abstract][Full Text] [Related]
9. "Off-label" use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions.
Dascalu AM; Popa-Cherecheanu A; Popa-Cherecheanu M; Nica A; Serban D
Rom J Ophthalmol; 2016; 60(2):90-95. PubMed ID: 29450329
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion.
Gokce G; Sobaci G; Durukan AH; Erdurman FC
Postgrad Med; 2013 Sep; 125(5):51-8. PubMed ID: 24113663
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
Ip MS; Gottlieb JL; Kahana A; Scott IU; Altaweel MM; Blodi BA; Gangnon RE; Puliafito CA
Arch Ophthalmol; 2004 Aug; 122(8):1131-6. PubMed ID: 15302652
[TBL] [Abstract][Full Text] [Related]
12. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion.
Ramezani A; Esfandiari H; Entezari M; Moradian S; Soheilian M; Dehsarvi B; Yaseri M
Acta Ophthalmol; 2014 Nov; 92(7):e530-9. PubMed ID: 24373344
[TBL] [Abstract][Full Text] [Related]
13. Central Retinal Vein Occlusion in 2 Patients Using Antipsychotic Drugs.
Taki K; Kida T; Fukumoto M; Sato T; Oku H; Ikeda T
Case Rep Ophthalmol; 2017; 8(2):410-415. PubMed ID: 28924438
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.
DeCroos FC; Ehlers JP; Stinnett S; Fekrat S
Curr Eye Res; 2011 Dec; 36(12):1164-70. PubMed ID: 21978179
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.
Iturralde D; Spaide RF; Meyerle CB; Klancnik JM; Yannuzzi LA; Fisher YL; Sorenson J; Slakter JS; Freund KB; Cooney M; Fine HF
Retina; 2006 Mar; 26(3):279-84. PubMed ID: 16508427
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections.
Alshareef RA; Garg SJ; Hsu J; Vander J; Park C; Spirn MJ
J Ocul Pharmacol Ther; 2014 Aug; 30(6):512-6. PubMed ID: 24828198
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.
Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M
Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385
[No Abstract] [Full Text] [Related]
19. Cytokine Kinetics after Monthly Intravitreal Bevacizumab for Retinal Vein Occlusion Associated with Macular Oedema.
Noma H; Mimura T; Yasuda K; Shimura M
Ophthalmic Res; 2016; 56(4):207-214. PubMed ID: 27160159
[TBL] [Abstract][Full Text] [Related]
20. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
